Longitudinal tumor ecosystem mapping defines glioblastoma treatment trajectories
Glioblastoma remains an invariably recurring and lethal brain tumor shaped by complex interactions between malignant and microenvironmental cells. How these interactions evolve under first-line standard-of-care (SOC) therapy remains unclear. We performed spatial single-cell profiling of 671 paired newly diagnosed and recurrent glioblastoma samples from 96 patients to map tumor-ecosystem evolution and its clinical relevance. We delineated five distinct patient subgroups, each characterized by unique ecosystem trajectories that correlated with clinical outcome. Patients whose tumors transitioned into oligodendrocyte-progenitor-like niches with enhanced vascular integrity, oxygenation and an IL10/CCL/MHCII immunomodulatory environment experienced improved clinical prognosis. In contrast, progression towards hypoxic mesenchymal/astrocyte-like niches dominated by strong LGALS1/SPP1/TGF{beta} immunosuppression predicted poor outcome. Furthermore, a subgroup of early-relapsing patients on SOC therapy that was characterized by a depletion of an antigen-presenting myeloid-cell-rich niche, exhibited diminished responsiveness to second-line lomustine therapy. Overall, mapping evolutions in glioblastoma ecosystems offers a novel framework for prognostic stratification and therapeutic guidance.